The launch of Tacrolimus capsules expands Biocon’s generic formulation portfolio in the US. 

On Monday, the stock had given a breakout above the neckline of a double bottom formation. This breakout is confirmed by the above 50-day average volume. Additionally, the stock had formed a sizeable bullish candle on the breakout day, which adds further strength to the breakout.

The stock of Coromandel International has given an ascending triangle breakout on the daily timeframe. Further, the breakout is supported by a robust volume of more than 3 times of the 50-day average volume, indicating a strong buying interest by the market participants.

Biocon: Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US. Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades. 

Fireworks are likely to continue on D-Street today also, as SGX Nifty indicates that Nifty could climb 50 points at the opening bell and open around 13,938.50 levels.

On the downside, Monday’s gap area of 13,771-13,811 is likely to act as a cushion in case of any dip or correction. We would advise the readers to maintain a positive yet cautious stance and avoid contrarian trades as long as the bulls continue to hold above the gap area.

The company on Monday announced its expansion plans in the eastern part of India. It informed that it will expand in the region with two of its brand products namely, Joy e-bike and Vyom Innovations.   

In the last few months, investors are continuously exiting from their mutual fund investment. Read on to find out why. 

After approving Sputnik-V from Dr Reddy’s Lab and Covaxin from Bharat Biotech, ZyCoV-D is the next one in line seeking permission to start phase III trials.  

Bharat Forge Ltd announced that the company has agreed to invest in  Avaada SataraMH Private Limited (ASPL) for the purchase of solar power as a group captive user and further, made an investment of around Rs 2.87 crore in terms of 28,70,000 equity shares of Rs 10 each in ASPL.